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doi:10.1016/j.ejvs.2008.07.008Abstract Background: Controversy exists regarding the best type of arteriovenous (AV)
fistula to be formed in secondary and tertiary access procedures when primary fistulas have
failed. This meta-analysis aimed to compare transposed brachial-basilic AV fistulas (BBAVFs)
with upper limb AV prosthetic grafts.
Methods: A literature search of the MEDLINE and SCOPUS databases was performed to identify
comparative studies reporting outcomes for both BBAVFs with upper limb AV prosthetic grafts.
Meta-analysis techniques were applied to identify differences in outcomes between the two
groups regarding primary and secondary 1-year failure rates.
Results: Eleven relevant studies, involving 1509 patients, met the inclusion criteria and were
incorporated in the final analysis; however, only one was randomised controlled trial. The
pooled odds’ ratio (OR) estimate for the primary and secondary failure rates at 1 year was
0.67 (CI 0.41e1.09) and 0.88 (CI 0.69e1.12), respectively, showing no difference in the
outcome between the two groups. The re-intervention rate was higher for prosthetic grafts
(0.54 per BBAVF versus 1.32 per graft). In a small subgroup of two studies comparing BBAVFs
with forearm grafts the pooled estimate for 1-year primary failure rate was in favour of the
BBAVF group (OR 0.3, CI 0.15e0.58, pZ 0.0004) suggesting that forearm grafts were inferior
having a 3-fold risk of failure at 1 year.
Conclusion: This analysis supports the use of BBAVF early in difficult access cases prior to the
use of prosthetic grafts. However, the latter conclusion is debatable due to heterogeneity,
small size and non-randomised design of the included studies.
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Radiocephalic and brachiocephalic arteriovenous (AV)
fistulas remain first and second in the order of preference
for incident patients who begin haemodialysis according to
the new updated DOQI guidelines.1 Controversy, however,
exists regarding the best type of fistula in secondary and
tertiary access procedures when primary fistulas have
failed. When forearm vessels are not suitable for radio-
cephalic or brachiocephalic AV fistulas alternatives include
either the brachial-basilic AV fistula (BBAVF) or the use of
a prosthetic graft as recommended by the updated DOQI
and European guidelines.1,2 In this study we perform
a meta-analysis aimed at comparing transposed BBAVF with
upper limb AV prosthetic grafts.
Methods
Search strategy
A literature search confined to studies published in English
or having English abstracts was performed using the elec-
tronic databases MEDLINE and SCOPUS up to February 2008.
The keywords used were ‘‘basilic vein transposition’’
‘‘brachiobasilic fistula’’, brachio-basilic fistula’’, ‘‘basilic
elevation’’ and ‘‘brachial basilic fistula’’. The references of
the retrieved articles were also reviewed for any additional
relevant articles. Data were independently extracted by
two reviewers. After reading 139 abstracts, relevant arti-
cles were printed for full accessment.
Inclusion criteria
To be included in the analysis, studies had to compare
BBAVF with any type of prosthetic AV upper limb grafts and
report on at least one of the outcome measures of primary
and secondary access patencies as specified by standards
recommended for reports dealing with AV access proce-
dures.3 Additionally all the included studies needed to have
at least 1-year follow-up.
Statistics
Data were extracted from the studies and entered into
a computer file. One-year patency rates were transformed
into a dichotomous outcome for the specific time period.
The access sites were assessed to be either patent or
thrombosed at the end of the time period. Primary and
secondary failure rates were extracted and used sepa-
rately. Data extraction was done from life tables, text or
graphs (Table 1). Statistical analysis was performed using
the available free software RevMan 4.2 (The Cochrane
Collaboration, 2003). Study effects were presented using
odds’ ratios (ORs). The OR represents the odds of an
adverse event occurring in the BBAVF group as compared
with the synthetic graft group. An OR< 1 indicated lower
failure rates of BBAVF whereas an OR >1 indicated lower
failure rates of synthetic grafts. The 95% confidence
intervals (CIs) describe the possible range that the OR could
take; any CI that included 1 (the point of equal effect of thetwo access options) was considered not to be statistically
significant. Subgroup analysis was undertaken for the
following groups: those comparing BBAVF with forearm
grafts and those comparing BBAVF with upper arm grafts.
The pooled results (OR and 95% CI) for all combined studies
as well as the subgroup results were calculated and
displayed using either fixed or random-effect models of
meta-analysis (Figs. 1 and 2). Unless evidence of between-
study heterogeneity existed, the fixed-effect model
(F.E.M.) was used. Heterogeneity between the included
studies was assessed using the Chi squared statistic and
assumes a null hypothesis of no difference between studies.
If the Chi squared statistic is non-significant it is assumed
that there is homogeneity across the studies and that F.E.M.
is appropriate. The random-effect model (R.E.M.) was used
when the alternative hypothesis was accepted, indicating
significant heterogeneity between studies. The I2 statistical
index was also used, as it does not rely on the number of
studies analyzed, I2 values >50% indicate significant
heterogeneity.4
The NewcastleeOttawa Scale (NOS) was used to assess
the quality of the non-randomised studies in this meta-
analysis. This scale was developed to assess the quality of
studies using a ‘star system’ (maximum nine stars) in which
a study is judged on three broad perspectives: the selection
of the study groups; the comparability of the groups; and
the ascertainment of outcome of interest.5 Only 4 out of
the 10 non-randomized studies had scores 7 stars
(Table 2)Results
Eleven relevant studies, involving 1509 patients, were
included in the final analysis (Table 1).6e16 Ten of these
studies were retrospective and one was a randomized
controlled trial. In these studies a total of 602 patients
underwent BBAVF creation and 907 patients AV grafts of
various materials and configurations (Table 1). Sample
sizes ranged from 70 to 283 patients. Two additional
relevant studies were excluded because the number of
patients at risk was not recorded in one and data dupli-
cation from a previous article was recognized in the
other.17,18
The pooled OR estimate for the primary failure rate at
1 year was 0.67 (CI 0.41e1.09) showing no difference in
the outcome between the two groups (pZ 0.11) (Fig. 1).
The pooled OR estimate for the secondary failure rate at 1
year was 0.88 (CI 0.69e1.12) showing no difference
(pZ 0.29) between the two groups (Fig. 2). In eight
studies reporting the total number of re-interventions, 255
re-interventions in 470 BBAVFs (0.54 per BBAVF) and 922
re-interventions in 694 grafts (1.32 per graft) were
recorded, respectively.6e10,12,15,16
We looked at several subgroups and compared BBAVFs
with upper arm grafts using data from eight relevant
studies.6,8e13,15 The pooled OR estimates for primary and
secondary failure rates at 1 year were 0.78 (CI 0.43e1.41)
and 0.86 (CI 0.66e1.11), respectively, showing no differ-
ence between the two groups. In contrast in a small
subgroup of two studies comparing BBAVFs with forearm
grafts the pooled OR estimates for primary and secondary
Table 1 Characteristics of studies included in the meta-analysis
Author Year F/UP Length Study type Data source Type of grafts
Kakkos et al.6 2008 20 months Controlled-comparativea Text All VECTRA upper arm
Keuter et al.7 2008 12 months RCTb Text All PTFE forearm
Torina et al.8 2008 13 months Retrospective Text All PTFE, upper
arm 95%
Weale et al.9 2007 >36 months Retrospective Text and graph All PTFE upper arm
Woo et al.10 2007 60 months Retrospective Life table All PTFE upper arm
Kawecka et al.11 2005 24 months Retrospective Text and graph PTFEz 90% Upper
armz 95%
Lee et al.12 2004 18 months Retrospective Graph All PTFE Upper arm
Oliver et al.13 2001 >24 months Retrospective Graph All PTFE Upper arm
Benedetto et al.14 2000 12 months Retrospective Text All PTFE CNSc
Matsuura et al.15 1998 >36 months Retrospective Graph All PTFE upper arm
Coburn and Carney16 1994 24 months Retrospective Text All PTFE z65% forearm
a Non-randomized.
b Randomized controlled trial.
c Configuration not stated.
Brachial-basilic fistulas versus prosthetic grafts 599failure rates at 1 year were 0.3 (CI 0.15e0.58) and 0.75 (CI
0.33e1.72), respectively (Figs. 1 and 2) showing that
primary failure rate was significantly increased in the
forearm AV grafts group (pZ 0.0004).7,16Discussion
Unlike other veins in the arm, the basilic vein lies deep
beneath the fascia and is protected from damage caused by
multiple venipunctures making it a valuable haemodialysis
conduit but necessitating superficialisation. The use of
a transposed basilic vein has an advantage that only oneStudy BBAVFs AV Grafts  
or sub-category  events/N events/N 
01 Forearm AV grafts
 Coburn  6/59              14/47
 Keuter 27/50              40/51
Subtotal (95% CI) 109                98
Total events: 33 (BBAVFs), 54 (AV Grafts)
Test for heterogeneity: Chi² = 0.07, df = 1 (P = 0.78), I² = 0%
Test for overall effect: Z = 3.54 (P = 0.0004)
02 Arm grafts
Matsuura  5/30              20/68
 Oliver 23/59              44/80
 Lee  6/20              15/50
Kawecka 49/85              47/90
 Weale 39/71              50/114 
Woo 35/119            110/164 
Kakkos 22/40              38/76
 Torina 23/42              47/94
Subtotal (95% CI) 466                736
Total events: 202 (BBAVFs), 371 (AV Grafts)
Test for heterogeneity: Chi² = 38.44, df = 7 (P < 0.00001), I² = 81.8%
Test for overall effect: Z = 0.81 (P = 0.42)
03 Unknown Configuration
Benedetto 14/27              40/73 
Subtotal (95% CI) 27                 73
Total events: 14 (BBAVFs), 40 (AV Grafts)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.79)
Total (95% CI) 602                907
Total events: 249 (BBAVFs), 465 (AV Grafts)
Test for heterogeneity: Chi² = 44.82, df = 10 (P < 0.00001), I² = 77.7%
Test for overall effect: Z = 1.60 (P = 0.11)
 0.1  0.2  0
 Favours BBA
Figure 1 Forest plot comparing the odds’ ratio (95% confidenc
prosthetic grafts.anastomosis is required and one avoids the venous anasto-
mosis the most common site of stenosis in prosthetic grafts.
The method was first reported by Dagher et al. some 30
years ago.19
Prosthetic grafts have some advantages over the BBAVF
in that these are easier to create, especially in obese
individuals and can be punctured earlier. In some cases,
a forearm graft can also be a useful alternative allowing the
venous system to mature, facilitating subsequent BBAVF
creation. BBAVF can always be created following a forearm
PTFE graft failure, assuming no previous extended dissec-
tion within the cubital fossa. The use of forearm grafts prior
to upper arm ones often is followed by more proximalOR (random)  OR (random)
95% CI  95% CI Year Quality
    0.27 [0.09, 0.76] 1994    D 
    0.32 [0.14, 0.77] 2008    A 
    0.30 [0.15, 0.58]
    0.48 [0.16, 1.43] 1998    D 
   0.52 [0.26, 1.04] 2001    D 
    1.00 [0.32, 3.10] 2004    D 
    1.25 [0.69, 2.26] 2005    D 
    1.56 [0.86, 2.83] 2007    D 
    0.20 [0.12, 0.34] 2007    D 
    1.22 [0.57, 2.64] 2008    D 
    1.21 [0.58, 2.51] 2008    D 
     0.78 [0.43, 1.41]
    0.89 [0.37, 2.15] 2000    D 
    0.89 [0.37, 2.15]
    0.67 [0.41, 1.09]
.5 1 2 5  10
VFs Favours  AV Grafts
e interval) of the 1-year primary failure rate of BBAVFs and
Study BBAVFs AV Grafts OR (fixed) OR (fixed)
or sub-category   events/N events/N  95% CI  95% CI Year  Quality
01 Forearm AV grafts
 Coburn 6/59               6/47     0.77 [0.23, 2.58]  1994    D 
 Keuter 6/50               8/51     0.73 [0.23, 2.29]  2008    A 
Subtotal (95% CI) 109                98     0.75 [0.33, 1.72]
Total events: 12 (BBAVFs), 14 (AV Grafts)
Test for heterogeneity: Chi² = 0.00, df = 1 (P = 0.95), I² = 0%
Test for overall effect: Z = 0.68 (P = 0.50)
02 Arm grafts
Matsuura 3/30              14/68     0.43 [0.11, 1.62]  1998    D 
 Oliver       22/59              30/80  0.99 [0.49, 1.99]  2001    D 
Kawecka       39/85              40/90     1.06 [0.58, 1.92]  2005    D 
 Weale       33/71              44/114     1.38 [0.76, 2.52]  2007    D 
Woo       29/119             64/164     0.50 [0.30, 0.85]  2007    D 
Kakkos 5/40              14/76     0.63 [0.21, 1.90]  2008    D 
 Torina       11/42              21/94     1.23 [0.53, 2.86]  2008    D 
Subtotal (95% CI) 446                686     0.86 [0.66, 1.11]
Total events: 142 (BBAVFs), 227 (AV Grafts)
Test for heterogeneity: Chi² = 9.12, df = 6 (P = 0.17), I² = 34.2%
Test for overall effect: Z = 1.16 (P = 0.25)
03 Unknown Configuration
Benedetto 9/27              18/73     1.53 [0.58, 3.99]  2000    D 
Subtotal (95% CI) 27                 73     1.53 [0.58, 3.99]
Total events: 9 (BBAVFs), 18 (AV Grafts)
Test for heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
Total (95% CI) 582                857     0.88 [0.69, 1.12]
Total events: 163 (BBAVFs), 259 (AV Grafts)
Test for heterogeneity: Chi² = 10.54, df = 9 (P = 0.31), I² = 14.6%
Test for overall effect: Z = 1.06 (P = 0.29)
 0.1  0.2  0.5 1 2 5 10
Favours BBAVFs  Favours AV Grafts
Figure 2 Forest plot comparing the odds’ ratio (95% confidence interval) of the 1-year secondary failure rate of BBAVFs and
prosthetic grafts.
600 M.K. Lazarides et al.revisions of the venous anastomosis, encroaching on the
basilic vein in the process and no upper arm autologous
options may remain afterwards. However, short-length
PTFE grafts can be used to replace short fibrotic segments
of the basilic vein at the elbow with good results, rendering
BBAVF creation feasible.20,21 Transposed BBAVFs have
disadvantages when compared with other fistulas. The
transposition procedure may create significant arm swelling
and pain as well as a greater incidence of steal than other
fistula types, and they are more technically challenging.1 In
comparison with brachiocephalic fistulas, BBAVFs are more
likely to mature, although they are more susceptible to late
thrombosis. BBAVFs have several advantages over forearm
or upper arm grafts, with less risk of infections and
thromboses.22
The results of this meta-analysis comparing 1-year
primary and secondary failure rates of BBAVFs versus
prosthetic grafts (ORZ 0.67 CI 0.41e1.09 and ORZ 0.88 CITable 2 NewcastleeOttawa quality assessment estimate
of the 10 included non-randomized studies
Selection Comparability Outcome
Kakkos et al. ++++ ++ +++
Oliver et al. ++ + ++
Lee et al. ++ + ++
Weale et al. ++++ ++ +++
Matsuura et al. +++ + +++
Benedetto et al. ++ +
Woo et al. +++ +++
Kawecka et al. ++ ++
Coburn and Carney +++ + ++
Torina et al. ++++ ++ ++0.69e1.12, respectively) indicate no difference in the
outcome between the two groups. There was a greater re-
intervention rate for prosthetic grafts (0.54 per BBAVF
versus 1.32 per graft). In a subgroup analysis including two
studies, forearm grafts were inferior to BBAVFs having
a 3-fold risk of failure at 1 year (ORZ 0.3, p< 0.0004). The
finding of statistical heterogeneity in the primary failure
rates and not in the secondary ones may be due to
a different degree of aggressiveness in revisions in the
various included studies. Some surgeons would support the
use forearm prosthetic grafts prior to any upper arm access
including BBAVF, based on the ‘‘distal sites first’’ policy.
The appropriateness of such a strategy is questionable
based on the findings of this meta-analysis. In order to
maintain patency, revisions in the elbow area may jeopar-
dize the future use of the basilic vein. We believe that all
autogenous BBAVF should be attempted first despite its
proximal level in the upper arm instead of a more distal
forearm graft. The latter is in accordance with the updated
DOQI guidelines in opposition to their previous version
where the two procedures were considered at the same
order of preference.1,23 BBAVFs should be considered early,
before prosthetic grafting, in the absence of a suitable
superficial vein. BBAVFs frequently do not mature in
patients older than 60 years, which compromises their
utility as a primary access.24 This is not the case though for
many patients as in a recent meta-analysis a significant
benefit was found in favour of proximal autogenous fistulas
over radial cephalic ones in the elderly.25 On the other
hand, in late referrals and females over 70 years of age and
those with unfavourable anatomy or on long-term steroids
more liberal use of synthetic grafts is justified.26
A limitation of this meta-analysis is that all but one of
the included studies is non-randomized series. Only 4 out of
Brachial-basilic fistulas versus prosthetic grafts 601the 10 non-randomized studies scored 7 stars in the
NewcastleeOttawa scale, a nine star quality assessment
tool developed to evaluate the quality of non-randomized
studies.5 The pooled data derived cannot provide level 1
evidence. Another weakness of this review is that BBAVFs
were analyzed as a homogenous group without taking into
consideration the various existing techniques. Simple
elevation, superficialisation (transposition), one stage and
two stage procedures have different reported outcomes.27
A recent review reported that BBAVFs are reliable
secondary access procedures with an average primary and
secondary 1-year patency of 60% and 72%, respectively.27
Secondary patency was favourable in older patients.28 The
updated DOQI guidelines rate BBAVFs as third choice after
radiocephalic or brachiocephalic AV fistulas. Our results are
debatable due to heterogeneity, small size and non-rand-
omised design of the included studies. There is a need for
more randomised controlled trials on this topic to allow
a definitive conclusion.Acknowledgements
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